Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of JNJ-78934804 versus guselkumab in moderately to severely active Crohn's disease
2026-525922-39-00Phase 3Authorised
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 30
01
Overview
Phase 3, randomised, double-blind trial in Crohn's disease comparing JNJ-78934804 arm with guselkumab active control arm (2 arms). Primary endpoints: Clinical remission at Week 48 and Endoscopic remission at Week 48. Planned start Aug 2026; status: authorised.
02
Drugs
guselkumab + golimumabguselkumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2026-525922-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525922-39-00.